BD MAX Assay (Becton, Dickinson and Company) for MRSA detection is EU approved

The BD MAX MRSA Assay, from BD Diagnostics, a Becton Dickinson company, for rapidly and accurately identifing methicllin-resistant Staphylococcus aureus (MRSA) in patients has received CE mark approval in the EU. The BD MAX is a fully automated, bench-top molecular system designed to perform a broad range of molecular testing. This offers the flexibility and versatility to perform CE/in vitro diagnostic (IVD) assays and user defined protocols on the same platform. The dual functionality of open system and CE/IVD capabilities on the BD MAX System enables laboratories to consolidate a broad range of molecular tests on a single workstation. This flexibility provides clinicians with the best information to make critical treatment and management decisions to improve patient care. There are now more than 20 assays in the BD MAX System's content-rich menu pipeline. The BD MAX System has also been approved by the FDA when used with BD MAX IVD assays (which have been approved by the FDA).